INTRODUCTION AND OBJECTIVES: Due to its metastatic nature, patients with castration-resistant prostate cancer (CRPC) are difficult to cure and very poor prognosis. To date, there is no effective therapeutic resume for this disease. Therefore, understanding molecular mechanisms of promoting metastasis in CRPC would help to improve therapies for the disease. Currently, numerous studies have indicated that microRNAs (miRNAs) are aberrantly expressed in several cancers, including CRPC. In this study, we constructed a miRNA expression signature to identify miRNA regulated RNA networks in CRPC using autopsy specimens from patients with androgen deprivation therapy (ADT) failure. Based on the signature, dual-strands of pre-miR-145 (miR-145-5p and miR-145-3p) were significantly reduced in CRPC specimens. We focused on the passenger strand miR-145-3p that was significantly reduced in CRPC tissues. The aim of this study was to investigate the functional significance of miR-145-3p and its regulated RNA networks in CRPC.
METHODS: Expression levels of miR-145-3p were evaluated in prostate needle biopsy specimens and autopsy CRPC specimens. Gain-of-function studies were performed by miR-145-3p transfection into PCa cells. Genome-wide gene expression analysis and in silico analysis were applied to investigate molecular targets regulated by miR-145-3p in PCa cells. TCGA database was applied to analyze cohort of CRPC patients.
RESULTS: Downregulation of miR-145-3p was validated in hormone naive PCa and CRPC specimens (P < 0.0001). Patients with lower expression of miR-145-3p tend to have shorter BCR-free interval (P ¼ 0.0739). Restoration of miR-145-3p significantly inhibited cancer cell migration and invasion in PCa cell lines (P < 0.0001). We identified 4 responsible genes (MELK, NCAPG, BUB1 and CDK1) by miR-145-3p regulation. The expressions of MELK, NCAPG, BUB1 and CDK1 were significantly elevated as tumour stage and lymph node stage advanced and all four genes significantly predicted disease-free survival of PCa patients (P < 0.0001, P ¼ 0.0002, P < 0.0001 and P < 0.0001, respectively). Moreover, these four genes were overexpressed in metastatic lesions of CRPC specimens by immunohistochemistry.
CONCLUSIONS: Dual-strand of tumor-suppressors, miR-145-5p and miR-145-3p, were identified based on miRNA signature. miR-145-3p regulated RNA networks were deeply involved in CRPC pathogenesis. Small RNA sequencing for lethal CRPC specimens and current in silico approaches provide us with novel therapeutic strategies for CRPC. INTRODUCTION AND OBJECTIVES: Elevated expression of miR-21, and androgen receptor (AR) regulated microRNA, is sufficient to induce castration resistant prostate cancer growth. However, the mechanism of miR-21-mediated castration resistance remains unclear. PDCD4 (programmed cell death 4) has been known as a tumor suppressor gene and also known as a potent target of miR-21. In this study, we identify PDCD4 as a check point of miR-21 induced castration resistant growth in human prostate cancer.
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METHODS: Hormone-sensitive prostate cancer cell lines (LNCaP, LAPC4) were used for this study. These cells were transiently transfected with miR-21 mimics, anti-PDCD4 siRNAs, or PDCD4 expression vectors (pCMV-PDCD4) and plated into three different media conditions (complete media, with Bicalutamide, androgen depleted) in order to evaluate PDCD4 function on androgen-dependent, castration resistant growth, and protein expression. In rescue experiments, cells were co-transfected with miR-21 and control or pCMV-PDCD4 vectors. Cell viability was evaluated by MTS assay. Protein expression levels were measured by western blotting.
RESULTS: Androgen stimulation elevates miR-21 expression and reduces PDCD4 protein expression ( Fig 1A) . Transfection with miR-21 inhibits PDCD4 protein expression in LNCaP and LAPC4 cells (25-40%), as well as luciferase reporters that contain the predicted miR-21 targeting regions from the PDCD4 3 0 UTR ( Fig 1B) . In addition, androgen deprivation reduces miR-21 expression and increases PDCD4 protein level ( Fig 1C) . miR-21 inhibitor blocked miR-21-induced PDCD4 protein suppression ( Fig 1B) . In cell viability assay, both miR-21 or anti-PDCD4 siRNA transfected cells induced cell growth and castration resistant cell growth (Fig 2A) . Moreover, miR-21 induced cell growth was inhibited by PDCD4 overexpression (Fig 2B) .
CONCLUSIONS: Our results demonstrate that miR-21 regulates PDCD4 protein expression, and that PDCD4 contributes to miR-21 induced cell growth and castration resistance. Therefore, PDCD4 could be a check point of miR-21 induced castration resistance. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1325
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MP99-15 TAXANE RESISTANCE IN PROSTATE CANCER: A ROLE FOR MIRNA 181A
Cameron Armstrong*, Chengfei Liu, Wei Lou, Christopher Evans, Allen Gao, Sacramento, CA INTRODUCTION AND OBJECTIVES: Docetaxel (DTX) is one of the primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to DTX therapy and their disease will continue to progress. The mechanisms by which resistance develops is still incompletely understood. This study seeks to determine the involvement of miRNAs, specifically miR-181a, in DTX resistance in CRPC.
METHODS: Total RNA from parental C4-2B prostate cancer cells and DTX resistant C4-2B cells (C4-2B TaxR) was submitted for small RNA deep sequencing. Data was analyzed to ascertain which miRNAs expressions were most altered in C4-2B TaxR cells compared to parental cells. Having identified an increase in miR-181a in resistant cells, its expression was modulated in C4-2B and C4-2B TaxR cells by transfecting them with miR-181a mimics or antisense, respectively. Following transfection, cell number was determined after 48 h with or without DTX. Cross resistance to cabazitaxel induced by miR-181a was also determined. Western blots were used to determine ABCB1 protein expression and rhodamine assays used to assess activity. Phospho-p53 expression was assessed by western blot and apoptosis was measured by ELISA in C4-2B TaxR cells with inhibited miR-181a expression with or without DTX.
RESULTS: miR-181a is significantly upregulated in C4-2B TaxR cells compared to parental C4-2B cells as analyzed by small RNA sequencing. Overexpression of miR-181a in C4-2B cells confers DTX and cabazitaxel resistance. Knockdown of miR-181a in C4-2B TaxR cells re-sensitizes them to treatment with both DTX and cabazitaxel. miR-181a knockdown alone induced apoptosis in C4-2B TaxR cells which is further enhanced by DTX. We next assessed if miR-181a altered expression or activity of ABCB1, which is overexpressed/active in C4-2B TaxR cells and promotes resistance to DTX by pumping the drug out of cells. We found that miR-181a does not impact ABCB1 expression or activity. Since we previously demonstrated that phospho-p53 can modulate DTX sensitivity, we determined if miR-181a can alter p53 expression in C4-2B TaxR cells. Knockdown of miR-181a in C4-2B TaxR cells induced phospho-p53 expression, suggesting that miR-181a induced resistance to DTX is mediated by inhibition of phospho-p53 expression.
CONCLUSIONS: Overexpression of mir-181a in C4-2B TaxR cells contributes to their resistance to DTX and inhibition of mir-181a expression can restore treatment response. This is due, in part, to modulation of p53 phosphorylation and induction of apoptosis.
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This work is supported in part by grants NIH/NCI This work was supported in part by grants NIH/NCI CA140468, CA168601, CA179970, and DOD PCRP PC150040. is the most common cancer diagnosed in males and the second leading cause of death from cancer in men. Despite the advances in cancer therapy, when PCa progress to castration resistant phase, patients develop incurable bone metastases. Therefore, understanding of the processes that regulate homing and survival of metastatic cancer cells in the bone is crucial for the identification of new therapies. TGF-b signaling plays a major role in bone remodeling and according to the 00 vicious cycle hypothesis 00 is a master regulator of maintenance of prostate cancer cells in lytic bone lesions. microRNAs (miRs) are a class of small non-coding RNAs that regulates many biological process. miR-221 expression has been previously associated with prostate cancer progression. Here we studied the effect of miR-221 on TGF-b signaling and the impact of miR-221 on tumor growth in vivo.
MP99-16
METHODS: miR-221 was overexpressed in PC3 and RWPE-1 cells and PMEPA was monitored by RT-qPCR and western blot. Expression of miR-221 in PC3 and RWPE-1 cells was assessed by RT-qPCR. Predicted targets were identified in silico (Targetscan and microRNA.org). Luciferase assay was used to investigate the interaction between miR-221 and PMEPA1. For zebrafish experiment, fluorescently labelled PC-3M-Pro4 cells overexpressing miR-221 were injected in the duct of cuvier of zebrafish embryos.
RESULTS: We found that miR-221 overexpression resulted in decreased PMEPA1 mRNA and protein in PC-3 human prostate cancer cells. PMEPA1 is a master regulator of TGF-b signaling and luciferase reporter assay revealed that miR-221 can directly interact with PMEPA1 3 0 UTR. Our experiments showed an enhancement of the proliferative effect of TGF-b in PC-3 cells, following enforced miR-221 expression. In conclusion, we observed increased Smad2 activation upon TGF-b treatment in miR-221 overexpressing PC-3 cells. Inoculation of fluorescently labelled highly metastatic PC-3M-Pro4 cells overexpressing miR-221 in the Duct of Cuvier (DC) of zebrafish embryos resulted reduced tumor burden compared to control. Finally, we found an inverse correlation between miR-221 and PMEPA1 expression in normal vs. tumor tissue collected from PCa patients.
CONCLUSIONS: Our results indicate that miR-221 is a regulator of TGF-b signaling via modulation of PMEPA1 and miR-221 overexpression can reduce tumor growth in vivo. Therefore, miR-221 represents an interesting molecule to target PCa and to interfere with the maintenance of PCa cells in the bone microenvironment. 197, No. 4S, Supplement, Tuesday, May 16, 2017 
